Stock Track | Bioventus Soars 8% as Q3 Earnings Top Estimates, Analysts Raise Targets

Stock Track11-06

Shares of Bioventus Inc. surged 8.36% on Tuesday, November 6, 2024, following the company's better-than-expected third-quarter earnings results and increased bullishness from analysts on Wall Street.

According to Bioventus's earnings report for the quarter ended September 30, 2024, the medical device company reported adjusted earnings per share of $0.06, exceeding analysts' consensus estimate of $0.03. Revenue rose 15% year-over-year to $138.96 million, also beating expectations of $133.23 million. However, the company reported a net loss of $4.82 million for the quarter.

Separately, in a research roundup published on November 6, Canaccord Genuity raised its price target on Bioventus to $15 from $12, reflecting increased optimism about the company's prospects. The current average analyst rating on the stock is "hold," with 2 "buy" ratings, no "holds," and 1 "sell" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184094694?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 16:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184094694","market":"us","top_or_hot":-1,"title":"Stock Track | Bioventus Soars 8% as Q3 Earnings Top Estimates, Analysts Raise Targets","media":"Stock Track","content":"<p>Shares of Bioventus Inc. surged 8.36% on Tuesday, November 6, 2024, following the company's better-than-expected third-quarter earnings results and increased bullishness from analysts on Wall Street.</p>\n\n<p>According to Bioventus's earnings report for the quarter ended September 30, 2024, the medical device company reported adjusted earnings per share of $0.06, exceeding analysts' consensus estimate of $0.03. Revenue rose 15% year-over-year to $138.96 million, also beating expectations of $133.23 million. However, the company reported a net loss of $4.82 million for the quarter.</p>\n\n<p>Separately, in a research roundup published on November 6, Canaccord Genuity raised its price target on Bioventus to $15 from $12, reflecting increased optimism about the company's prospects. The current average analyst rating on the stock is \"hold,\" with 2 \"buy\" ratings, no \"holds,\" and 1 \"sell\" rating.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bioventus Soars 8% as Q3 Earnings Top Estimates, Analysts Raise Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bioventus Soars 8% as Q3 Earnings Top Estimates, Analysts Raise Targets\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 16:06 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Bioventus Inc. surged 8.36% on Tuesday, November 6, 2024, following the company's better-than-expected third-quarter earnings results and increased bullishness from analysts on Wall Street.\n...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BVS","symbol_name":"Bioventus Inc.","start_time":0,"source_url":"","article_id":"1184094694","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184094694","pubTimestamp":1730880404,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bioventus Inc. surged 8.36% on Tuesday, November 6, 2024, following the company's better-than-expected third-quarter earnings results and increased bullishness from analysts on Wall Street.According to Bioventus's earnings report for the quarter ended September 30, 2024, the medical device company reported adjusted earnings per share of $0.06, exceeding analysts' consensus estimate of $0.03. Revenue rose 15% year-over-year to $138.96 million, also beating expectations of $133.23 millio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BVS":"Bioventus Inc."},"translate_title":"Bioventus股价飙升8%，第三季度盈利高于预期，分析师上调目标","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVS":1},"content_text":"Shares of Bioventus Inc. surged 8.36% on Tuesday, November 6, 2024, following the company's better-than-expected third-quarter earnings results and increased bullishness from analysts on Wall Street.\nAccording to Bioventus's earnings report for the quarter ended September 30, 2024, the medical device company reported adjusted earnings per share of $0.06, exceeding analysts' consensus estimate of $0.03. Revenue rose 15% year-over-year to $138.96 million, also beating expectations of $133.23 million. However, the company reported a net loss of $4.82 million for the quarter.\nSeparately, in a research roundup published on November 6, Canaccord Genuity raised its price target on Bioventus to $15 from $12, reflecting increased optimism about the company's prospects. The current average analyst rating on the stock is \"hold,\" with 2 \"buy\" ratings, no \"holds,\" and 1 \"sell\" rating.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184094694"}